Education
About Us
Working with TipRanks
Follow Us
Sol-Gel Technologies (SLGL)
NASDAQ:SLGL
SLGL Stock Chart & Stats
$65.27
-$0.16(-11.43%)
At close: 4:00 PM EST
$65.27
-$0.16(-11.43%)
Day’s Range― - ―
52-Week Range$4.01 - $75.00
Previous CloseN/A
Volume503.92K
Average Volume (3M)16.66K
Market Cap
$183.25M
Enterprise Value$167.33M
Total Cash (Recent Filing)$30.47M
Total Debt (Recent Filing)$1.39M
Price to Earnings (P/E)―
Beta1.65
Next Earnings
May 08, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.13
Shares Outstanding2,785,787
10 Day Avg. Volume26,975
30 Day Avg. Volume16,656
Financial Highlights & Ratios
PEG Ratio0.39
Price to Book (P/B)8.98
Price to Sales (P/S)22.45
P/FCF Ratio-18.65
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue25.51
Enterprise Value/Gross Profit-16.62
Enterprise Value/Ebitda-10.19
Forecast
1Y Price Target
$110.00Price Target Upside68.53% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Analyst Valuation UpliftAnalyst's higher price target and revised commercial assumptions reflect increased confidence in SGT-610's market potential and can bolster investor sentiment.
First-in-class Market OpportunityApproval of SGT-610 as the first therapy to prevent new basal cell carcinoma lesions in Gorlin syndrome would establish a unique treatment category and support strong specialist adoption.
Peak Commercial PotentialAnalyst projects SGT-610 could achieve peak annual revenue above $300 million, highlighting meaningful upside if uptake expands through broader indications by 2035.
Bears Say
Clinical Development RiskFailure of the SGT-610 pivotal trial or inability to secure U.S. regulatory approval would sharply curtail revenue expectations and likely prompt a significant stock revaluation.
Financing And Dilution RiskPotential need for additional capital to advance programs could lead to shareholder dilution, weighing on valuation if financing requirements increase.
Program Discontinuation ImpactDiscontinuation of the SGT-210 program after negative clinical results underscores execution risk and raises questions about the consistency of clinical outcomes across the pipeline.
Sol-Gel Technologies News
SLGL FAQ
What was Sol-Gel Technologies’s price range in the past 12 months?
Sol-Gel Technologies lowest stock price was $4.01 and its highest was $75.00 in the past 12 months.
What is Sol-Gel Technologies’s market cap?
Sol-Gel Technologies’s market cap is $183.25M.
When is Sol-Gel Technologies’s upcoming earnings report date?
Sol-Gel Technologies’s upcoming earnings report date is May 08, 2026 which is in 86 days.
How were Sol-Gel Technologies’s earnings last quarter?
Sol-Gel Technologies released its earnings results on Nov 06, 2025. The company reported -$2.13 earnings per share for the quarter, missing the consensus estimate of -$2.09 by -$0.04.
Is Sol-Gel Technologies overvalued?
According to Wall Street analysts Sol-Gel Technologies’s price is currently Undervalued.
Does Sol-Gel Technologies pay dividends?
Sol-Gel Technologies does not currently pay dividends.
What is Sol-Gel Technologies’s EPS estimate?
Sol-Gel Technologies’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Sol-Gel Technologies have?
Sol-Gel Technologies has 2,785,787 shares outstanding.
What happened to Sol-Gel Technologies’s price movement after its last earnings report?
Sol-Gel Technologies reported an EPS of -$2.13 in its last earnings report, missing expectations of -$2.09. Following the earnings report the stock price went down -2.141%.
Which hedge fund is a major shareholder of Sol-Gel Technologies?
Currently, no hedge funds are holding shares in SLGL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Sol-Gel Technologies Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$110.00 (68.53% Upside)
$110.00 (68.53% Upside)
Insider Transactions
Bought Shares
Worth $3.7M over
the Last 3 Months
the Last 3 Months
Technicals
SMA
Positive
20 days / 200 days
Momentum
682.16%
12-Months-Change
Fundamentals
Return on Equity
-29.59%
Trailing 12-Months
Asset Growth
-19.52%
Trailing 12-Months
Company Description
Sol-Gel Technologies
Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has completed Phase III clinical trials for the treatment of acne vulgaris; Epsolay, a once-daily topical cream that has completed Phase III clinical trials for the treatment of papulopustular rosacea; SGT-210, which is in Phase I clinical trial for the treatment of palmoplantar keratoderma; and Erlotinib, Tapinarof, and roflumilast to treat psoriasis and other medical conditions. It is also involved in the development of generic topical dermatological drug products. The company has collaboration with Perrigo. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel.
SLGL Stock 12 Month Forecast
Average Price Target
$110.00
▲(68.53% Upside)
Technical Analysis
Insight Molecular Diagnostics
―
Ovid Therapeutics
―
Shattuck Labs
―
Surrozen
―
Metagenomi, Inc.
―
Ownership Overview
16.51% Insiders
0.05% Mutual Funds
11.76% Other Institutional Investors
71.69% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---